摘要
谷氨酸盐,一个主要的兴奋神经递质,在突触可塑性,例如长时程增强和新突触形成中扮演着重要角色。越来越多的证据表明谷氨酸盐信号涉及精神病的神经生物学当中,包括精神分裂症、重度抑郁症(MDD)和躁郁症(BP)。大脑解剖学研究表明患有这些精神疾病的病人的大脑脊柱密度发生了改变,暗示了改造过的神经元环路可能导致这些精神疾病的病理学。以谷氨酸系统为靶点的药物已经广泛引起了人们的注意,因为他们在动物模型中显示了效果且在临床试验中显现了潜在的治疗作用。尤其,N-甲基-D-天冬氨酸盐(NMDA)受体拮抗剂,氯胺酮在治疗抵抗的MDD和BP患者治疗过程中发挥了快速的和强劲的抗抑郁的作用,而传统的抗抑郁药发挥治疗作用需要几周时间。动物试验表明氯胺酮诱导快速的突触发生,暗示经由NMDA受体信号传导的突触可塑性是治疗抑郁症的必要环节。因此,药物调节谷氨酸信号也可能成为治疗精神病的潜在药物。首先,我们总结了谷氨酸信号在树突棘形成,维护和重塑中的作用。然后,我们讨论了从精神疾病的大脑解剖学研究和动物模型研究中得到证实的树突棘和谷氨酸信号的异常情况。最后,我们对作用于NMDA受体的药物在精神疾病的临床和动物模型中所表现得潜在优点进行了综述。
关键词: 动物模型,谷氨酸盐,情感障碍,NMDA受体,后期研究,精神分裂症,脊柱密度
Current Molecular Medicine
Title:Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders
Volume: 15 Issue: 3
Author(s): Y. Ohgi, T. Futamura and K. Hashimoto
Affiliation:
关键词: 动物模型,谷氨酸盐,情感障碍,NMDA受体,后期研究,精神分裂症,脊柱密度
摘要: Glutamate, a major excitatory neurotransmitter, plays important roles in synaptic plasticity, such as long-term potentiation (LTP) and new synapse formation. Growing evidence suggests that glutamate signaling is involved in the neurobiology of psychiatric disorders, including schizophrenia, major depressive disorder (MDD) and bipolar disorder (BP). Postmortem brain studies demonstrated altered spine density in brains from patients with these psychiatric disorders, indicating that remodeled neuronal circuits may contribute to the pathobiology of these psychiatric diseases. Drugs targeting the glutamate system have typically attracted attention as they show efficacy in animal studies and potential therapeutic effects in the clinical setting. In particular, the Nmethyl- D-aspartate (NMDA) receptor antagonist, ketamine exerts a rapid and robust antidepressant effect in treatment-resistant patients with MDD and BP, whereas conventional antidepressants require several weeks for therapeutic onset. Animal studies showed that ketamine induced rapid synaptogenesis, suggestive of synaptic plasticity via NMDA receptor signaling being an essential event in the treatment of depression. Therefore, drugs modulating glutamate signaling could also be potential therapeutic drugs for psychiatric disorders. First, we summarize the role of glutamate signaling on dendritic spine formation, maintenance and remodeling. Then, we discuss the abnormalities identified in dendritic spine and glutamate signaling from postmortem brain studies and animal models of psychiatric disorders. Finally, we review the potential benefits of drugs acting on the NMDA receptor in clinical and animal models of psychiatric disorders.
Export Options
About this article
Cite this article as:
Y. Ohgi, T. Futamura and K. Hashimoto , Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders, Current Molecular Medicine 2015; 15 (3) . https://dx.doi.org/10.2174/1566524015666150330143008
DOI https://dx.doi.org/10.2174/1566524015666150330143008 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obstetrical Hemorrhage Review
Current Women`s Health Reviews Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Pathophysiology of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
Current Medicinal Chemistry Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry Exploring the SARS-Cov-2 Main Protease (M<sup>pro</sup>) and RdRp Targets by Updating Current Structure-based Drug Design Utilizing Co-crystals to Combat COVID-19
Current Drug Targets An Erythroid-Enriched Endoribonuclease (ErEN) Involved in α -Globin mRNA Turnover
Protein & Peptide Letters Molecular Pathways Involved in the Early and Late Damage Induced by Testis Ischemia: Evidence for a Rational Pharmacological Modulation
Current Medicinal Chemistry Vascular Oxidative Stress: A Key Factor in the Development of Hypertension Associated with Ethanol Consumption
Current Hypertension Reviews The Ultrasonographic Diagnosis of Polycystic Ovary Syndrome
Current Medical Imaging Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy